Pacira BioSciences, Inc.
PCRX
$22.56
-$0.13-0.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.67% | -0.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.67% | -0.87% | |||
| Cost of Revenue | 38.19% | 39.22% | |||
| Gross Profit | -4.74% | -13.46% | |||
| SG&A Expenses | 10.69% | 3.63% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.73% | -3.26% | |||
| Operating Income | -117.55% | 44.02% | |||
| Income Before Tax | -94.00% | 594.24% | |||
| Income Tax Expenses | -126.05% | 40.14% | |||
| Earnings from Continuing Operations | -69.86% | 212.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -69.86% | 212.07% | |||
| EBIT | -117.55% | 44.02% | |||
| EBITDA | -14.95% | -20.88% | |||
| EPS Basic | -68.78% | 215.67% | |||
| Normalized Basic EPS | -124.20% | 1,479.21% | |||
| EPS Diluted | -67.92% | 209.09% | |||
| Normalized Diluted EPS | -124.14% | 1,466.29% | |||
| Average Basic Shares Outstanding | -3.51% | -3.13% | |||
| Average Diluted Shares Outstanding | -3.32% | -2.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||